ERBB2 and breast carcinoma: Additional data are needed to establish whether incidence of HER2+ tumours, which are ER−, remains low since their treatment involves monoclonal antibodies, such as trastuzumab and pertuzumab,13,50 which are amongst the more expensive breast cancer treatments used by the NHS.